TheraRadar
Clinical-Stage Companies / Kissei Pharmaceutical

Kissei Pharmaceutical

Pre-Approval PRO BETA
28
Total Trials
17
Phase 3
10
Phase 2
3
Recruiting
351
Score

Pipeline by Phase

Phase 3
17
Phase 2
10
Phase 1
2

Therapeutic Focus

Endometriosis Parkinson Disease Spinocerebellar Degeneration Uremic Pruritus Uterine Fibroids (MeSH Heading: Leiomyoma)

Clinical Trials (28)

NCT07040137 Phase 3 RECRUITING

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration

Started: 7/1/2025

NCT07015268 Phase 3 ACTIVE NOT RECRUITING

A Clinical Study of KLH-2109 in Patients With Endometriosis

Started: 6/9/2025

NCT05445167 Phase 3 COMPLETED

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain

Started: 10/11/2022

NCT04711603 Phase 3 COMPLETED

A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Started: 1/16/2021

NCT04132050 Phase 3 COMPLETED

A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788

Started: 12/24/2019

NCT03986944 Phase 3 TERMINATED

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Started: 5/23/2019

NCT04372121 Phase 3 TERMINATED

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain

Started: 3/23/2020

NCT04335591 Phase 3 COMPLETED

Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)

Started: 3/5/2020

NCT03992846 Phase 3 COMPLETED

Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain.

Started: 6/13/2019

NCT05440383 Phase 3 COMPLETED

A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia

Started: 10/11/2022

NCT02912533 Phase 3 COMPLETED

A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Started: 9/1/2016

NCT02912494 Phase 3 COMPLETED

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Started: 9/1/2016

NCT01970098 Phase 3 COMPLETED

A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Started: 10/9/2013

NCT02889302 Phase 3 COMPLETED

An Additional Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD)

Started: 11/15/2016

NCT01850641 Phase 3 COMPLETED

A Phase III Study of PA21 With Calcium Carbonate in Hemodialysis Patients With Hyperphosphatemia

Started: 4/29/2013

NCT01850602 Phase 3 COMPLETED

A Phase III Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Started: 4/23/2013

NCT01833494 Phase 3 COMPLETED

A Long-term Study of PA21 in Hemodialysis Patients With Hyperphosphatemia

Started: 3/18/2013

NCT06722729 Phase 2 ACTIVE NOT RECRUITING

A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease

Started: 12/16/2024

NCT03802617 Phase 2 COMPLETED

A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus.

Started: 2/1/2019

NCT05831670 Phase 2 COMPLETED

An Early Phase 2 Clinical Study of KSP-0243

Started: 4/27/2023

NCT04867551 Phase 2 COMPLETED

A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease

Started: 5/15/2021

NCT03845387 Phase 2 COMPLETED

A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.

Started: 2/26/2019

NCT02778919 Phase 2 COMPLETED

Late Phase II Clinical Study of KLH-2109 in Patients With Endometriosis

Started: 5/9/2016

NCT01521494 Phase 2 COMPLETED

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

Started: 1/11/2012

NCT02343978 Phase 2 COMPLETED

Phase II Study of KWA-0711 in Patients With Chronic Constipation (CC)

Started: 12/26/2014

NCT02281630 Phase 2 COMPLETED

Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC)

Started: 10/15/2014

NCT03177668 Phase 1 COMPLETED

Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma

Started: 8/8/2017

NCT03068481 Phase 1 COMPLETED

Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease

Started: 2/20/2017

Drug Candidates

KDT-3594 Placebo KLH-2109 Leuprorelin acetate MR13A9 R788 KPS-0373 75 mg linzagolix tablet 200 mg linzagolix tablet Add-back capsule (E2 1 mg / NETA 0.5 mg)
Activity Status: Active
Last Trial Started: 7/1/2025
Last Trial Ended: 10/18/2024
Trials (12 months): 2
Completed Trials: 23
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.